Effects of diabetic HDL on endothelial cell function

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 14, Issue 2, 2014, Pages 137-141

  He, Dan ^a   Pan, Bing ^a   Ren, Hui ^b   Zheng, Lemin ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Diabetes mellitus; Dysfunction; Endothelial dysfunction; High density lipoprotein

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ENDOTHELIUM DERIVED RELAXING FACTOR; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SPHINGOSINE 1 PHOSPHATE; TRIACYLGLYCEROL;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL ADHESION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; ENZYME ACTIVITY; GLYCATION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN PHOSPHORYLATION; RISK FACTOR; SIGNAL TRANSDUCTION; VASODILATATION; ANIMAL; CELL MOTION; CHEMISTRY; METABOLISM; PATHOLOGY;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 2; ENDOTHELIAL CELLS; HUMANS; LIPOPROTEINS, HDL; NITRIC OXIDE;

EID: 84905570745     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871529X14666140505124415     Document Type: Article

References (47)

1. Laight, D.W.; Carrier, M.J.; Anggård, E.E. Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy, Diabetes Metab. Res. Rev., 1999, 15, 274-282.
2. Bonetti, P.O.; Lerman, L.O.; Lerman, A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 168-175.
3. Félétou, M.; Vanhoutte, P.M. Endothelial dysfunction: a multifaceted disorder (the Wiggers award lecture). Am. J. Physiol. Heart Circ. Physiol., 2006, 291, H985-H1002.
4. Sena, C.M.; Pereira, A.M.; Seica, R. Endothelial dysfunction-A major mediator of diabetic vascular disease, Biochim. Biophys. Acta., 2013, 1832, 2216-2231.
5. Nofer, J.R.; van der Giet, M.; Tolle, M.; Wolinska, I.;von Wnuck Lipinski, K.; Baba, H.A.; Tietge, U.J.;Godecke. A.; Ishii, I.; Kleuser, B.; Schafers, M.; Fobker, M.; Zidek, W.; Assmann, G.; Chun, J.; Levkau, B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest., 2004, 113, 569-581.
6. Terasaka, N.; Wang, N.; Yvan-Charvet, L.; Tall, A.R. High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Proc. Natl. Acad. Sci. US A, 2007, 104, 15093-15098.
7. Giannotti, G.; Doerries, C.; Mocharla, P.S.; Mueller, M.F.; Bahlmann, F.H.; Horvàth, T.; Jiang, H.; Sorrentino, S.A.; Steenken, N.; Manes, C.; Marzilli, M.; Rudolph, K.L.; Lüscher, T.F.; Drexler, H.; Landmesser, U. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension, 2010, 55, 1389-1397.
8. Pan, B.; Ma, Y.; Ren, H.; He, Y.; Wang, Y.; Lv, X.; Liu, D.; Ji, L.; Yu, B.; Wang, Y.; Chen, Y.E.; Pennathur, S.; Smith, J.D.; Liu, G.; Zheng, L. Diabetic HDL is dysfunctional in stimulating endothelial cell migration and proliferation due to down regulation of SR-BI expression. PLoS One, 2012, 7, e48530.
9. Van Linthout, S.; Spillmann, F.; Schultheiss, H.P.; Tschöpe, C. High-density lipoprotein at the interface of type 2 diabetes mellitus and cardiovascular disorders. Curr. Pharm. Des., 2010, 16, 1504-1516.
10. Landmesser, U.; Hornig, B.; Drexler, H. Endothelial function: a critical determinant in atherosclerosis? Circulation, 2004, 109, II27-II33.
11. Drew, B.G.; Fidge, N.H.; Gallon-Beaumier, G.; Kemp, B.E.; Kingwell, B.A. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc. Natl. Acad. Sci. USA, 2004, 101, 6999-7004.
12. Riwanto, M.; Landmesser, U. High-density lipoproteins and Endothelial Functions: Mechanistic Insights and Alterations in Cardiovascular Disease. J. Lipid Res., 2013, 54(12), 3227-43.
13. Nofer, J.R.; van der Giet, M.; Tölle, M.; Wolinska, I.; von Wnuck Lipinski, K.; Baba, H.A.; Tietge, U.J.; Gödecke, A.; Ishii, I.; Kleuser, B.; Schäfers, M.; Fobker, M.; Zidek, W.; Assmann, G.; Chun, J.; Levkau, B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest., 2004, 113, 569-581.
14. Sorrentino, S.A.; Besler, C.; Rohrer, L.; Meyer, M.; Heinrich, K.; Bahlmann, F.H.; Mueller, M.; Horváth, T.; Doerries, C.; Heinemann, M.; Flemmer, S.; Markowski, A.; Manes, C.; Bahr, M.J.; Haller, H.; von Eckardstein, A.; Drexler, H.; Landmesser, U. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation, 2010, 121, 110-122.
15. Perségol, L.; Vergès, B.; Foissac, M.; Gambert, P.; Duvillard, L. Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia, 2006, 49, 1380-1386.
16. Nobécourt, E.; Jacqueminet, S.; Hansel, B.; Chantepie, S.; Grimaldi, A.; Chapman, M.J.; Kontush, A. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia, 2005, 48, 529-538.
17. Baker, P.W.; Rye, K.A.; Gamble, J.R.; Vadas, M.A.; Barter, P.J. Ability of reconstituted high density lipoproteins to inhibit cytokineinduced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J. Lipid Res., 1999, 40, 345-353.
18. Gowri, M.S.; Van der Westhuyzen, D.R.; Bridges, S.R.; Anderson, J.W. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 2226-2233.
19. Brindisi, M.C.; Duvillard, L.; Monier, S.; Vergès, B.; Perségol, L. Deleterious effect of glycation on the ability of HDL to counteract the inhibitory effect of oxidized LDL onendothelium-dependent vasorelaxation. Diabetes Metab. Res. Rev., 2013, 29(8), 618-2
20. Duell, P.B.; Oram, J.F.; Bierman, E.L. Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes, 1999, 40, 377-384.
21. Triggle, C.R.; Samuel, S.M.; Ravishankar, S.; Marei, I.; Arunachalam, G.; Ding, H. The endothelium: influencing vascular smooth muscle in many ways. Can. J. Physiol. Pharmacol., 2012, 90, 713-738.
22. Tao, J.; Yan, C.; Tian, X.; Liu, S.; Li, Y.; Zhang, J.; Sun, M.; Ma, X.; Han, Y. CREG Promotes the Proliferation of Human Umbilical Vein Endothelial Cells through the ERK/Cyclin E Signaling Pathway. Int. J. Mol. Sci., 2013, 14, 18437-18456.
23. Seetharam, D.; Mineo, C.; Gormley, A.K.; Gibson, L.L.; Vongpatanasin, W.; Chambliss, K.L.; Hahner, L.D.; Cummings, M.L.; Kitchens, R.L.; Marcel, Y.L.; Rader, D.J.; Shaul, P.W. Highdensity lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-Btype I. Circ. Res., 2006, 98, 63-72.
24. Zhu, W.; Saddar, S.; Seetharam, D.; Chambliss, K.L.; Longoria, C.; Silver, D.L.; Yuhanna, I.S.; Shaul, P.W.; Mineo, C. The cavenger receptor class B type I adaptorprotein PDZK1 maintains endothelial monolayer integrity. Circ. Res., 2008, 102, 480-487.
25. Mineo, C.; Yuhanna, I.S.; Quon, M.J.; Shaul, P.W., High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J. Biol. Chem., 2003, 278, 9142-9149.
26. Pan, B.; Ren, H.; Ma, Y.; Liu, D.; Yu, B.; Ji, L.; Pan, L.; Li, J.; Yang, L.; Lv, X.; Shen, X.; Chen, B.; Zhang, Y.; Willard, B.; He, Y.; Zheng, L. High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells. Int. J. Cancer., 2012, 131, 70-82.
27. Tepper, O.M.; Galiano, R.D.; Capla, J.M.; Kalka, C.; Gagne, P.J.; Jacobowitz, G.R.; Levine, J.P.; Gurtner, G.C. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation, 2002, 106, 2781-2786.
28. van Oostrom, O.; Nieuwdorp, M.; Westerweel, P.E.; Hoefer, I.E.; Basser, R.; Stroes, E.S.; Verhaar, M.C. Reconstituted HDL increases circulating endothelial progenitor cells in patients with type 2 diabetes. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 1864-1865.
29. Murata, N.; Sato, K.; Kon, J.; Tomura, H.; Yanagita, M.; Kuwabara, A.; Ui, M.; Okajima, F. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem. J., 2000, 352, 809-815.
30. Huang, C.Y.; Lin, F.Y.; Shih, C.M.; Au, H.K.; Chang, Y.J.; Nakagami, H.; Morishita, R.; Chang, N.C.; Shyu, K.G.; Chen, J.W. Moderate to high concentrations of high-density lipoprotein from healthy subjects paradoxically impair humanendothelial progenitor cells and related angiogenesis by activating Rho-associated kinase pathways. Arterioscler. Thromb. Vasc. Biol., 2012, 32, 2405-2417.
31. Argraves, K.M.; Argraves, W.S. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J. Lipid Res., 2007, 48, 2325-2333.
32. Walter, D.H.; Rochwalsky, U.; Reinhold. J.; Seeger, F.; Aicher, A.; Urbich, C.; Spyridopoulos, I.; Chun, J.; Brinkmann, V.; Keul, P.; Levkau, B.; Zeiher, A.M.; Dimmeler, S.; Haendeler, J. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 275-282.
33. Rodríguez, C.; González-Díez, M.; Badimon, L.; Martínez-González, J. Sphingosine-1-phosphate: A bioactive lipid that confers highdensity lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb. Haemost., 2009, 101, 665-673.
34. Serrano-Sanchez, M.; Tanfin, Z.; Leiber, D. Signaling pathways involved in sphingosine kinase activation and sphingosine-1-phosphate release in rat myometrium in late pregnancy: role in the induction of cyclooxygenase 2. Endocrinology, 2008, 149, 4669-4679.
35. Nodai, A.; Machida, T.; Izumi, S.; Hamaya, Y.; Kohno, T.; Igarashi, Y.; Iizuka, K.; Minami, M.; Hirafuji, M. Sphingosine 1-phosphate induces cyclooxygenase-2 via Ca2+-dependent, but MAPK-independent mechanism in rat vascular smooth muscle cells. Life Sci., 2007, 80, 1768-1776.
36. Liu, D.; Ji, L.; Wang, Y.; Zheng, L. Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoprotein. Cardiovasc. Hematol. Disord. Drug Targets, 2012, 12, 98-105.
37. Tong, X.; Peng, H.; Liu, D.; Ji, L.; Niu, C.; Ren, J.; Pan, B.; Hu, J.; Zheng, L.; Huang, Y. High-density lipoprotein of patients with Type 2 diabetes mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate. Cardiovasc. Diabetol., 2013,12, 27.
38. Kontush, A.; Chapman, M.J. Why is HDL functionally deficient in type 2 diabetes? Curr. Diab. Rep., 2008, 8, 51-59.
39. Liu, D.; Ji, L.; Zhang, D.; Tong, X.; Pan, B.; Liu, P.; Zhang, Y.; Huang, Y.; Su, J.; Willard, B.; Zheng, L. Nonenzymatic glycation of high-density lipoprotein impairs its anti-inflammatory effects in innate immunity. Diabetes Mateb. Res. Rev., 2012, 28, 186-195.
40. Vita, J.A.; Brennan, M.L.; Gokce, N.; Mann, S.A.; Goormastic, M.; Shishehbor, M.H.; Penn, M.S.; Keaney, JF J.r.; Hazen, S.L. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation, 2004, 110, 1134-1139.
41. Nicholls, S.J.; Hazen, S.L. The role of myeloperoxidase in the pathogenesis of coronary artery disease. Japan J. Infect. Dis., 2004, 57, S21-S22.
42. Zheng, L.; Nukuna, B.; Brennan, M.L.; Sun, M.; Goormastic, M.; Settle, M.; Schmitt, D.; Fu, X.; Thomson, L.; Fox, P.L.; Ischiropoulos, H.; Smith, J.D.; Kinter, M.; Hazen, S.L. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest., 2004, 114, 529-541.
43. Pan, B.; Yu, B.; Ren, H.; Willard, B.; Pan, L.; Zu, L.;, Shen, X.; Ma, Y.; Li, X.; Niu, C.; Kong, J.; Kang, S.;, Eugene Chen, Y.; Pennathur, S.; Zheng, L. High-density lipoprotein nitration and chlorination catalyzed by myeloperoxidase impair its effect of promoting endothelial repair. Free Radic. Biol. Med., 2013, 60, 272-281.
44. Woodman, R.J.; Chew, G.T.; Watts, G.F. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. Drugs, 2005, 65, 31-74.
45. Kurosaki, Y.; Tsukushi, T.; Munekata, S.; Akahoshi, T.; Moriya, T.; Ogawa, Z. Semiquantitative analysis of apolipoprotein A-I modified by advanced glycation end products in diabetes mellitus. J. Clin. Lab. Anal., 2013, 27, 231-236.
46. Matsunaga, T.; Iguchi, K.; Nakajima, T.; Koyama, I.; Miyazaki, T.; Inoue, I.; Kawai, S.; Katayama, S.; Hirano, K.; Hokari, S.; Komoda, T. Glycated high-density lipoprotein induces apoptosis of endothelial cells via a mitochondrial dysfunction. Biochem. Biophys. Res. Commun., 2001, 287, 714-720.
47. Rye. K.A. Biomarkers associated with high-density lipoproteins in atherosclerotic kidney disease. Clin. Exp. Nephrol., 2014, 18(2), 247-50.